drugset / Trial / NCT02594254
Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects
Phase 2
Completed
135 enrolled
Armata Pharmaceuticals, Inc.
Agility Clinical, Inc. · collabSynteractHCR · collabVantage Data Designs, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate if C16G2 Gel administered over a certain period of time either with a toothbrush or a custom dental tray can effectively kill bacteria in the mouth that cause dental cavities.
Timeline
- Start
- 2015-11
- Primary completion
- 2016-06
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C16G2 | Peptide | 4 ml | Other |
| Subject | C16G2 | Peptide | 800 unknown | Other |
| Subject | C16G2 | Peptide | 1600 unknown | Other |